ORAMED PHARMACEUTICALS INC.

Nasdaq:ORMP

Pharmaceutical Preparations·NEW YORK, NY

, is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem.

CEO

Kidron Nadav

CFO

Gabay Avraham

All Filings(905 total)

TypeDateAccessionPeriodSize

8-K

Feb 20, 2026

0001012975-26-0001958-K

Feb 19, 2026

738.9 KB

SCHEDULE 13D/A

Feb 19, 2026

0001213900-26-018576

—

19.2 KB

SCHEDULE 13G/A

Feb 13, 2026

0001012975-26-000138

—

8.3 KB

SCHEDULE 13G/A

Feb 9, 2026

0001373604-26-000012

—

8.1 KB

SCHEDULE 13D

Jan 29, 2026

0001213900-26-009570

—

38.1 KB

Jan 29, 2026

0001213900-26-009477

Jan 22, 2026

7.4 KB

Jan 29, 2026

0001213900-26-009478

Jan 22, 2026

7.4 KB

Jan 29, 2026

0001213900-26-009476

Jan 22, 2026

7.4 KB

Jan 29, 2026

0001213900-26-009479

Jan 22, 2026

7.4 KB

Jan 21, 2026

0001213900-26-006215

Jan 14, 2026

4.9 KB

8-K

Jan 14, 2026

0001213900-26-004382CURRENT REPORT

Jan 12, 2026

1.9 MB

8-K

Jan 7, 2026

0001213900-26-001983CURRENT REPORT

Jan 7, 2026

193.5 KB

Jan 5, 2026

0001213900-26-001282

Dec 31, 2025

6.7 KB

Jan 5, 2026

0001213900-26-001280

Dec 31, 2025

9.8 KB

Jan 5, 2026

0001213900-26-001279

Dec 31, 2025

9.2 KB

Jan 5, 2026

0001213900-26-001278

Dec 31, 2025

9.2 KB

Jan 5, 2026

0001213900-26-001277

Dec 31, 2025

7.5 KB

Jan 5, 2026

0001213900-26-001275

Dec 31, 2025

6.6 KB

Jan 2, 2026

0001213900-26-000661

Dec 31, 2025

6.7 KB

Jan 2, 2026

0001213900-26-000658

Dec 31, 2025

9.2 KB

8-K

Dec 31, 2025

0001213900-25-127133CURRENT REPORT

Dec 31, 2025

184.5 KB

8-K

Dec 31, 2025

0001012975-25-0009928-K

Dec 30, 2025

156.1 KB

8-K

Nov 17, 2025

0001213900-25-111310CURRENT REPORT

Nov 17, 2025

194.8 KB

8-A12B

Nov 17, 2025

0001213900-25-111299FOR REGISTRATION OF CERTAIN CLASSES

—

274.4 KB

8-K

Nov 17, 2025

0001213900-25-111298CURRENT REPORT

Nov 16, 2025

502.8 KB

25 filings shown